Victoria L Stevens1, Ying Wang2, Brian D Carter2, Mia M Gaudet2, Susan M Gapstur2. 1. Behavioral and Epidemiology Research Group, American Cancer Society, 250 Williams St, NW, Atlanta, GA, 30329, USA. Victoria.Stevens@cancer.org. 2. Behavioral and Epidemiology Research Group, American Cancer Society, 250 Williams St, NW, Atlanta, GA, 30329, USA.
Abstract
INTRODUCTION: Postmenopausal hormone use is linked to several health outcomes and the risk associated with some may differ depending on whether estrogen is used alone or in combination with progestin. OBJECTIVE: Metabolomic analyses of postmenopausal hormone use and differences between hormone regimes was done to identify metabolites associated with each type of hormone treatment. METHODS: Untargeted metabolomics analysis was done on serum from 1336 women enrolled in the Cancer Prevention II Nutrition Cohort. Levels of 781 named metabolites were compared between 667 nonusers with 332 estrogen-only and with 337 estrogen plus progestin users using linear regression. Metabolite levels were also compared between estrogen-only and estrogen plus progestin users. RESULTS: Compared to nonusers, 276 metabolites were statistically significantly (P < 6.40 × 10- 5) associated with estrogen-only use and 222 were associated with estrogen plus progestin use. The metabolites associated with both types of hormones included numerous lipids, acyl carnitines, and amino acids as well as the thyroid hormone thyroxine and the oncometabolite fumarate. The 65 metabolites that differed significantly between estrogen-only and estrogen plus progestin users included 19 steroids and 12 lipids that contained the bioactive fatty acid arachidonic acid. CONCLUSIONS: These findings suggest that postmenopausal hormone use influences metabolic pathways linked to a variety of cellular processes, including the regulation of metabolism and stress responses, energy production, and inflammation. The differential association of numerous lipids which influence cellular signaling suggests that differences in signal transduction may contribute to the disparate risks for some diseases between estrogen-only and estrogen plus progestin users.
INTRODUCTION: Postmenopausal hormone use is linked to several health outcomes and the risk associated with some may differ depending on whether estrogen is used alone or in combination with progestin. OBJECTIVE: Metabolomic analyses of postmenopausal hormone use and differences between hormone regimes was done to identify metabolites associated with each type of hormone treatment. METHODS: Untargeted metabolomics analysis was done on serum from 1336 women enrolled in the Cancer Prevention II Nutrition Cohort. Levels of 781 named metabolites were compared between 667 nonusers with 332 estrogen-only and with 337 estrogen plus progestin users using linear regression. Metabolite levels were also compared between estrogen-only and estrogen plus progestin users. RESULTS: Compared to nonusers, 276 metabolites were statistically significantly (P < 6.40 × 10- 5) associated with estrogen-only use and 222 were associated with estrogen plus progestin use. The metabolites associated with both types of hormones included numerous lipids, acyl carnitines, and amino acids as well as the thyroid hormone thyroxine and the oncometabolite fumarate. The 65 metabolites that differed significantly between estrogen-only and estrogen plus progestin users included 19 steroids and 12 lipids that contained the bioactive fatty acidarachidonic acid. CONCLUSIONS: These findings suggest that postmenopausal hormone use influences metabolic pathways linked to a variety of cellular processes, including the regulation of metabolism and stress responses, energy production, and inflammation. The differential association of numerous lipids which influence cellular signaling suggests that differences in signal transduction may contribute to the disparate risks for some diseases between estrogen-only and estrogen plus progestin users.
Authors: JoAnn E Manson; Rowan T Chlebowski; Marcia L Stefanick; Aaron K Aragaki; Jacques E Rossouw; Ross L Prentice; Garnet Anderson; Barbara V Howard; Cynthia A Thomson; Andrea Z LaCroix; Jean Wactawski-Wende; Rebecca D Jackson; Marian Limacher; Karen L Margolis; Sylvia Wassertheil-Smoller; Shirley A Beresford; Jane A Cauley; Charles B Eaton; Margery Gass; Judith Hsia; Karen C Johnson; Charles Kooperberg; Lewis H Kuller; Cora E Lewis; Simin Liu; Lisa W Martin; Judith K Ockene; Mary Jo O'Sullivan; Lynda H Powell; Michael S Simon; Linda Van Horn; Mara Z Vitolins; Robert B Wallace Journal: JAMA Date: 2013-10-02 Impact factor: 56.272
Authors: Stacey N Reinke; Shama Naz; Romanas Chaleckis; Hector Gallart-Ayala; Johan Kolmert; Nazanin Z Kermani; Angelica Tiotiu; David I Broadhurst; Anders Lundqvist; Henric Olsson; Marika Ström; Åsa M Wheelock; Cristina Gómez; Magnus Ericsson; Ana R Sousa; John H Riley; Stewart Bates; James Scholfield; Matthew Loza; Frédéric Baribaud; Per S Bakke; Massimo Caruso; Pascal Chanez; Stephen J Fowler; Thomas Geiser; Peter Howarth; Ildikó Horváth; Norbert Krug; Paolo Montuschi; Annelie Behndig; Florian Singer; Jacek Musial; Dominick E Shaw; Barbro Dahlén; Sile Hu; Jessica Lasky-Su; Peter J Sterk; Kian Fan Chung; Ratko Djukanovic; Sven-Erik Dahlén; Ian M Adcock; Craig E Wheelock Journal: Eur Respir J Date: 2022-06-30 Impact factor: 33.795
Authors: Raji Balasubramanian; Olga Demler; Marta Guasch-Ferré; Nina P Paynter; Ryan Sheehan; Simin Liu; JoAnn E Manson; Jordi Salas-Salvadó; Miguel Á Martínez-Gonzalez; Frank B Hu; Clary Clish; Kathryn M Rexrode Journal: Circ Genom Precis Med Date: 2020-11-03
Authors: Mathilde His; Vivian Viallon; Laure Dossus; Audrey Gicquiau; David Achaintre; Augustin Scalbert; Pietro Ferrari; Isabelle Romieu; N Charlotte Onland-Moret; Elisabete Weiderpass; Christina C Dahm; Kim Overvad; Anja Olsen; Anne Tjønneland; Agnès Fournier; Joseph A Rothwell; Gianluca Severi; Tilman Kühn; Renée T Fortner; Heiner Boeing; Antonia Trichopoulou; Anna Karakatsani; Georgia Martimianaki; Giovanna Masala; Sabina Sieri; Rosario Tumino; Paolo Vineis; Salvatore Panico; Carla H van Gils; Therese H Nøst; Torkjel M Sandanger; Guri Skeie; J Ramón Quirós; Antonio Agudo; Maria-Jose Sánchez; Pilar Amiano; José María Huerta; Eva Ardanaz; Julie A Schmidt; Ruth C Travis; Elio Riboli; Konstantinos K Tsilidis; Sofia Christakoudi; Marc J Gunter; Sabina Rinaldi Journal: BMC Med Date: 2019-09-24 Impact factor: 8.775